Genmab A/S (NASDAQ:GMAB) Raised to “Strong-Buy” at Wall Street Zen

Genmab A/S (NASDAQ:GMAB) was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Friday.

A number of other equities research analysts also recently issued reports on GMAB. HC Wainwright increased their price objective on shares of Genmab A/S from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Friday, August 15th. Guggenheim upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target for the company in a report on Tuesday, September 23rd. Truist Financial raised their price target on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, July 8th. Finally, Zacks Research lowered shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $40.00.

Genmab A/S Stock Up 0.8%

NASDAQ:GMAB opened at $29.07 on Friday. The firm has a market cap of $18.65 billion, a PE ratio of 14.61, a price-to-earnings-growth ratio of 1.70 and a beta of 0.93. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $29.51. The company’s 50-day moving average price is $24.96 and its two-hundred day moving average price is $22.06.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.15. The firm had revenue of $925.00 million during the quarter, compared to analysts’ expectations of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. On average, research analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Osaic Holdings Inc. increased its holdings in shares of Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares during the last quarter. Captrust Financial Advisors boosted its position in shares of Genmab A/S by 2.4% during the second quarter. Captrust Financial Advisors now owns 22,442 shares of the company’s stock worth $464,000 after buying an additional 526 shares during the period. Rhumbline Advisers boosted its position in shares of Genmab A/S by 3.2% during the first quarter. Rhumbline Advisers now owns 16,956 shares of the company’s stock worth $332,000 after buying an additional 532 shares during the period. CWM LLC boosted its position in shares of Genmab A/S by 50.5% during the second quarter. CWM LLC now owns 1,797 shares of the company’s stock worth $37,000 after buying an additional 603 shares during the period. Finally, Yousif Capital Management LLC boosted its holdings in Genmab A/S by 7.8% in the second quarter. Yousif Capital Management LLC now owns 10,943 shares of the company’s stock valued at $226,000 after purchasing an additional 790 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.